Journal article 65 views 8 downloads
Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes
Immunotherapy Advances, Volume: 2, Issue: 1
PDF | Version of Record
© The Author(s) 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial LicenseDownload (13.62MB)
Antigen-specific immunotherapy is an immunomodulatory strategy for autoimmune diseases, such as type 1 diabetes, in which patients are treated with autoantigens to promote immune tolerance, stop autoimmune β-cell destruction and prevent permanent dependence on exogenous insulin. In this study, human...
|Published in:||Immunotherapy Advances|
Oxford University Press (OUP)
Check full text
No Tags, Be the first to tag this record!
Antigen-specific immunotherapy is an immunomodulatory strategy for autoimmune diseases, such as type 1 diabetes, in which patients are treated with autoantigens to promote immune tolerance, stop autoimmune β-cell destruction and prevent permanent dependence on exogenous insulin. In this study, human proinsulin peptide C19-A3 (known for its positive safety profile) was conjugated to ultrasmall gold nanoparticles (GNPs), an attractive drug delivery platform due to the potential anti-inflammatory properties of gold. We hypothesised that microneedle intradermal delivery of C19-A3 GNP may improve peptide pharmacokinetics and induce tolerogenic immunomodulation and proceeded to evaluate its safety and feasibility in a first-in-human trial. Allowing for the limitation of the small number of participants, intradermal administration of C19-A3 GNP appears safe and well tolerated in participants with type 1 diabetes. The associated prolonged skin retention of C19-A3 GNP after intradermal administration offers a number of possibilities to enhance its tolerogenic potential, which should be explored in future studies.
gold nanoparticle, peptide immunotherapy, microneedle, type 1 diabetes, proinsulin
Faculty of Medicine, Health and Life Sciences
This work has been funded through the EE-ASI (The Enhanced
Epidermal Antigen Specific Immunotherapy Against Type
1 Diabetes) European research network (Collaborative
Project) supported by the European Commission under the
Health Cooperation Work Programme of the 7th Framework
Programme (grant no. N 305305).